Spatial Metabolomics Reveals How Tirzepatide Inhibits Colorectal Cancer via Glucose Metabolic Reprogramming We are excited to share a recent publication in Advanced Science titled The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Attenuates Colon Cancer Development by Regulating Glucose Metabolism. In this study, the authors employed spatial metabolomics services provided by MetwareBio to explore the metabolic mechanisms by which tirzepatide (TZP)a dual GIP and GLP-1 receptor agonist initially approved for type 2 diabetesexerts potent anti-tumor effects in colorectal cancer (CRC)
It also targets certain appetite receptors in your brain, bringing down hunger more
For patients who struggle with cravings, large portions, or frequent hunger, semaglutide may make it easier to follow a nutrition plan
Gastrointestinal Effects While not always welcome, mild gastrointestinal symptoms such as nausea, decreased appetite, or altered bowel habits can indicate that the medication is engaging its target receptors
Prioritizing stress management techniques and ensuring adequate rest can help maintain optimal levels
But most trials only last 6-12 months